Business, energy, technology, markets and global industry news from Business News Today

retinal disease

PharmaDeviceNews retinal disease
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More
Representative image: An ophthalmology clinic scene showing retinal imaging and eye examination technology, reflecting Kodiak Sciences’ KSI-101 clinical data in macular edema secondary to inflammation and the growing role of biologics in inflammatory retinal disease treatment.
Pharma & Biotech

Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?

Steroids still dominate MESI care. Kodiak’s KSI-101 may test whether local biologics can change inflammatory retina treatment.

Read More
Pharma & Biotech

One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race

Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.

Read More
Representative image of retinal injection research and ophthalmology diagnostics used to illustrate Innovent Biologics’ Phase 3 efdamrofusp alfa breakthrough in neovascular age-related macular degeneration treatment.
Pharma & Biotech

Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data

Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.

Read More
Pharma & Biotech

What GenSight Biologics’ French CUA decision means for LHON gene therapy

France grants compassionate use access to GenSight Biologics’ LUMEVOQ for LHON. Explore what this decision changes and what risks remain.

Read More